Market Signal Briefing

GN Store Nord A/S (OTCPK:GNNDY) Q3 2025 Earnings Call November 6, 2025 5:00 AM EST

Company Participants

Rune Sandager - Head of Investor Relations
Peter Karlstromer - Chief Executive Officer
Soren Jelert - Chief Financial Officer

Conference Call Participants

Andjela Bozinovic - BNP Paribas, Research Division
Carsten Madsen - Danske Bank A/S, Research Division
Veronika Dubajova - Citigroup Inc., Research Division
Martin Parkhoi - SEB, Research Division
Niels Granholm-Leth - DNB Carnegie, Research Division
Martinien Rula - Jefferies LLC, Research Division
Susannah Ludwig - Sanford C. Bernstein & Co., LLC., Research Division
Julien Ouaddour - BofA Securities, Research Division
Martin Brenoe - Nordea Markets, Research Division
Richard Felton - Goldman Sachs Group, Inc., Research Division
Oliver Metzger - ODDO BHF Corporate & Markets, Research Division

Presentation

Rune Sandager
Head of Investor Relations

Hello, everyone, and welcome to GN's conference call in relation to our Q3 report announced this morning. Participating in today's call is Group CEO, Peter Karlstromer; Group CFO, Soren Jelert; and myself, Rune Sandager, Head of Investor Relations.

The presentation is expected to last about 20 minutes, after which we'll turn to the Q&A session. The presentation is already uploaded on gn.com. And with that, I'm happy to hand over to Peter for some opening remarks.

Peter Karlstromer
Chief Executive Officer

Thank you, Rune, and thanks to all of you for joining us today. Let me start with the group highlights on Slide 4. In Q3, we delivered a solid quarter with 1% organic revenue growth, driven by market share gains and strong performance across our divisions.

Our execution led to a healthy margin and cash flow development, allowing us to reconfirm our guidance for the year. In Hearing, the rollout of ReSound Vivia is continuing progressing very well. Vivia's strong differentiation and our solid commercial execution led to broad-based market share gains and 7% organic growth.

Overall, we are

Recommended For You

SES S.A. (OTCPK:SGBAF) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Christian Kern - Head of Investor Relations Adel Al-Saleh - Chief Executive Officer Elisabeth Pataki - Chief Financial Officer Conference Call Participants Paul Sidney - Joh. Berenberg, Gossler & Co. KG, Research Division Terence Tsui - Morgan Stanley, Research Division Ben Rickett - New Street Research LLP Roshan Ranjit - Deutsche Bank AG, Research Division Nick Dempsey - Barclays Bank PLC, Research Division Aleksander Peterc - Sanford C.

Simon Pryce
CEO & Executive Director

Thanks very much, and good morning, everyone. Welcome to the RS Group Interim Results Call for the 6-month period ending 30th September 2025, and thank you all for joining us this morning.

The presentation should take around 30 minutes, and then we'll have some time at the end for questions. But we'll try and make sure that we finish the call by no later than 10:00.

I'm going to start by summarizing our pleasing first half performance. Kate will then run through our in-line financials and what's driving them, both at a group and a regional level. Then I'll conclude by sharing with you the good underlying progress that we're making as we make the business better at RS and position ourselves to accelerate growth, improve efficiency, and drive better operating leverage over time.

But before we get into the details of this morning's presentation, we'd like to start our meetings, virtual or physical, at RS with a health and safety moment and a values highlight. So although we're virtual, please make sure you do take a safety moment to identify your nearest exit and safest evacuation route in the event of an emergency.

For our values highlight, I would just like to call out and celebrate our new multi-year global partnership with SolarAid to support their mission to light up lives across rural Africa. As our new global charity partner, their and our purposes and values are completely aligned that is one team delivering brilliantly, doing the right

Caterpillar Inc. (CAT) Analyst/Investor Day November 4, 2025 10:00 AM EST

Company Participants

Alex Kapper - Vice President of Investor Relations
Joseph Creed - CEO & Director
Jason Kaiser - Group President
Anthony Fassino - Group President of Construction Industries Group
Denise Johnson - Group President of Resource Industries
Bob De Lange - Group President of Services, Distribution & Digital
Andrew R. Bonfield - Chief Financial Officer

Conference Call Participants

Jamie Cook - Truist Securities, Inc., Research Division
Angel Castillo Malpica - Morgan Stanley, Research Division
Kyle Menges - Citigroup Inc., Research Division
Jerry Revich
Jairam Nathan - Daiwa Securities Co. Ltd., Research Division
Mircea Dobre - Robert W. Baird & Co. Incorporated, Research Division
Stephen Volkmann - Jefferies LLC, Research Division
Charles Albert Dillard - Sanford C. Bernstein & Co., LLC., Research Division
Robert Wertheimer - Melius Research LLC
Michael Feniger - BofA Securities, Research Division
Adam Seiden - Barclays Bank PLC, Research Division
Kristen Owen - Oppenheimer & Co. Inc., Research Division
Steven Fisher - UBS Investment Bank, Research Division
Tami Zakaria - JPMorgan Chase & Co, Research Division
Sabahat Khan - RBC Capital Markets, Research Division
Michael Shlisky - D.A. Davidson & Co., Research Division

Presentation

Alex Kapper
Vice President of Investor Relations

Good morning, everyone, and welcome to Caterpillar's 2025 Investor Day, the next 100 years. I'm Alex Kapper, Vice President, Investor Relations, and we're pleased to host you, whether you're joining online or in the room. And we're really excited to share with you how we see the next chapter of our story unfold. Just a few quick reminders before we get started. We've already conducted the safety briefing here in the room, and so I'd encourage anyone joining remotely to be aware of their surroundings and their local safety protocols.

During our event today, we'll make forward-looking statements, which are subject to risks and uncertainties. We'll make assumptions that could cause our actual results to be different

Recommended For You

, /PRNewswire/ -- A record-breaking field of more than 17,500 runners filled the streets of downtown Indianapolis today for the 18th annual CNO Financial Indianapolis Monumental Marathon, Half Marathon and 5K. The 13th consecutive sellout of the event showcased elite performances, including a new men's marathon course and event record and 14 athletes achieving qualifying times for the 2028 U.S. Olympic Team Trials – Marathon.

The Men's Champion, Joseph Whelan, broke the tape in 2:12:29, setting a new men's marathon course record and solidifying his place among the fastest marathoners ever to race in Indianapolis. On the women's side, Amanda Mosborg delivered a victory in 2:32:01, leading a strong field of competitors that included several returning champions and Trials qualifiers.

In total, 14 athletes earned 2028 U.S. Olympic Team Trials qualifying marks in the marathon distance, further establishing the CNO Financial Indianapolis Monumental Marathon as a key stop on the national competitive circuit.

Beyond the elite performances, the 2025 event featured a new start line on West Street, the largest marathon field in event history and the 10th anniversary of CNO Financial Group's title sponsorship. More than 6,600 marathoners earned their finisher medals and participants represented all 50 states and 22 countries, underscoring the event's growing global reach.

Results:

CNO Financial Indianapolis Monumental Marathon
Men's Champion: Joseph Whelan of Webster, N.Y., broke the finish tape and set a new course record with a winning time of 2:12:29. Ben Decker of Cambridge, Mass., and Andrew Bowman of Ferndale, Mich., finished second and third in a time of 2:15:23 and 2:15:33, respectively.

Women's Champion: Amanda Mosborg of St. Paul, Minn., finished first overall in a time of 2:32:01. Lucy Dobbs of Indianapolis crossed the line second with a time of 2:32:42, and Anna Benedettini of Virginia Beach, Va., finished third, coming in at 2:33:12.

CNO Financial Indianapolis Monumental Half Marathon
Men's Champion: Skylar Stidam of Bloomington, Ind., led the men's race and finished first in a time of 1:02:47. Second-place finisher Curtis Eckstein of Batesville, Ind., ran a time of 1:03:06, and third-place finisher Alec Basten of St. Louis, Mo., crossed the line in a time of 1:03:15.

Women's Champion: Carrie Ellwood of Boulder, Colo., won the women's race in a time of 1:08:33. Kasandra Parker of Waverly, Iowa, finished in second place with a time of 1:10:18, and Molly Grabill of Lafayette, Colo., finished in third at 1:11:00.

CNO Financial Indianapolis Monumental 5K
Men's Champion: Scott Spaanstra of Indianapolis, in 14:38.
Women's Champion: Sammy McClintock, Flagstaff, Ariz., in 16:17.

Other Highlights:

The 2025 event featured the 13th consecutive sellout and welcomed 17,500 participants from every U.S. state and 22 countries.
For the second consecutive year, the CNO Financial Indianapolis Monumental Marathon featured a record number of marathon finishers in the largest field ever.
Beyond Monumental's Run for a Cause program saw more than 240 participants run with a charity, such as Team World Vision, American Foundation for Suicide Prevention, International Justice Mission and more, all of which served to raise funds and awareness as they trained for the race.

This marks CNO Financial Group's 10th year as the title sponsor of its hometown marathon. CNO's partnership with Beyond Monumental underscores the organizations' shared commitment to health, wellness and the central Indiana community. The sponsorship continues to provide significant growth opportunities for Indy's premier running event.

Full results, when available, can be found here.

Plans are already underway for next year's event, scheduled for Saturday, Nov. 7, 2026. Participants can secure their spot for 2026 this weekend at monumentalmarathon.com. Registration closes Sunday, Nov. 9 and will reopen for the tradition of special Monumental Resolution pricing on Jan. 1, 2026.

About Beyond Monumental
Beyond Monumental, the 501(c)3 non-profit responsible for the CNO Financial Indianapolis Monumental Marathon, provides the Indianapolis community with a complement of activities built around their premiere event that promotes healthy living & fitness for all ages. Beyond Monumental gives back to the Indianapolis community by supporting youth programming that reinforces healthy lifestyles for young people, with an emphasis on working with urban students and Indianapolis Public Schools, donating over $1.7 million since inception. The CNO Financial Indianapolis Monumental Marathon is a top 15 marathon in the US and is nationally recognized by Runners' World as one of "Ten Great Marathons for First Timers". The 19th annual running is scheduled for Nov. 7, 2026. For more information, please visit beyondmonumental.org.

About CNO Financial Group
CNO Financial Group, Inc. (NYSE: CNO) secures the future of middle-income America. CNO provides life and health insurance, annuities, financial services and workforce benefits solutions through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National. Our customers work hard to save for the future, and we help protect their health, income and retirement needs with 3.3 million policies and $38.3 billion in total assets. Our 3,300 associates, 4,900 exclusive agents and more than 6,500 independent partner agents guide individuals, families and businesses through a lifetime of financial decisions. For more information, visit CNOinc.com.

SOURCE CNO Financial Group

Amazon (NASDAQ:AMZN) absolutely knocked one out of the ballpark this quarterly earnings season.

NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of America’s Car-Mart, Inc. (NASDAQ: CRMT) resulting from allegations that America’s Car-Mart, Inc. may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased America’s Car-Mart, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On September 4, 2025, during market hours, Benzinga published an article entitled “America’s Car-Mart Stock Plunges After Sales Volume Dip, Delinquency Uptick.” The article stated that America’s Car-Mart, Inc. stock was trading “lower after the company reported first-quarter results. The company reported a first-quarter loss of 69 cents per share, compared with a net loss of 15 cents per share in the year-ago period.”

On this news, America’s Car-Mart, Inc. stock fell 18.2% on September 4, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran’s Differentiated Profile –

− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac Parameters –

– In a Cohort of HELIOS-B Patients, CMR Imaging Showed Amyloid Regression in 22% of Vutrisiran Treated Patients with No Regression Found in Patients Who Received Placebo –

– Treatment with Vutrisiran Preserved Kidney Function in HELIOS-B Patients, and Reduced Risk of Death and Cardiovascular Events in Patients with Advanced Chronic Kidney Disease –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from cardiovascular magnetic resonance (CMR) and echocardiographic imaging as well as renal function analyses were presented at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana.

As a multisystem disease, ATTR-CM can impact the health and function of organs throughout the body. These analyses evaluated the effect of vutrisiran on critical measures of heart function and structure as well as kidney health, providing deeper insight into its potential impact on key organs affected by the disease.

HELIOS-B Analyses: Cardiac Structure, Function, and Amyloid Burden

In ATTR-CM, amyloid deposits in the heart lead to thickening and stiffening of the ventricles, affecting how well the heart functions and increasing the risk of heart failure and death. Advanced imaging techniques offer insights into structural and functional changes, capturing the overall burden of amyloid deposits and their impact on cardiac function.

A CMR analysis evaluated a retrospectively identified cohort of HELIOS-B patients from the National Amyloidosis Centre in London who underwent serial CMR scans as part of their routine clinical care at baseline (N=43), Year 1 (N=39), Year 2 (N=26), and Year 3 (N=17).

A mixed model analysis that pooled 24- and 36-month data found that treatment with vutrisiran monotherapy was associated with nominally statistically significant and directionally favorable changes in multiple measures of cardiac structure, function, and amyloid burden, including improvements in left and right ventricular ejection fractions as well as stroke volumes and left ventricular mass, compared to placebo.

Treatment with vutrisiran also reduced extracellular volume (ECV), which is thought to reflect amyloid buildup in the heart. At Year 3, amyloid regression, as assessed by ECV, was observed in 22% of patients treated with vutrisiran, while no patients who received placebo showed regression; conversely, progression occurred in 63% of patients who received placebo compared to 11% of patients treated with vutrisiran.

At Year 3, patients treated with vutrisiran exhibited an absolute mean (standard deviation) reduction in ECV of -0.10% (± 4.72) versus an increase of 7.86% (± 5.67) in the placebo group (p=0.006).

To further assess cardiac function in patients with ATTR-CM, echocardiographic parameters including left atrial strain (LAS) and right ventricular free wall strain (RVFWS) were evaluated in analyses of the overall HELIOS-B population.

The LAS analysis demonstrated that measures of LAS were associated with baseline disease severity, mortality, and cardiovascular (CV) events, and that patients treated with vutrisiran experienced less worsening in LAS at 30 months, compared to those receiving placebo.

The RVFWS analysis showed that worse RVFWS was associated with higher risk of adverse outcomes and that treatment with vutrisiran stabilized RVFWS at 30 months, compared to placebo.

“As ATTR-CM progressively damages the heart muscle, making it thicker, stiffer, and less capable of pumping blood effectively, patients experience worsening symptoms, quality of life, and outcomes,” said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. “The HELIOS-B CMR analysis provides compelling initial evidence that treatment with vutrisiran can counteract these changes in some patients, as shown by favorable impacts on measures of cardiac structure and function as well as regression of amyloid burden. These results suggest that vutrisiran has the potential not only to slow disease progression, but to reverse some of the structural damage caused by amyloid deposition in the heart in some patients.”

HELIOS-B Analysis: Renal Function and CV Outcomes in Patients with Severe Chronic Kidney Disease (CKD)

Kidney involvement is common in patients with ATTR-CM and is associated with disease progression along with worse patient outcomes as amyloid deposits in the kidneys can lead to a decline in kidney function, indicated by a decreasing estimated glomerular filtration rate (eGFR).

A post hoc analysis of the HELIOS-B study evaluated the impact of vutrisiran on renal function and assessed the efficacy and safety of vutrisiran in patients who advanced to severe CKD during the double-blind period. Outcomes, including the composite endpoint of all-cause mortality (ACM) and recurrent CV events, as well as safety, were assessed in patients who advanced to CKD Stage 4 or greater (eGFR < 30 mL/min/1.73 m²) in the overall population, vutrisiran monotherapy population, and baseline tafamidis treatment group.

In the overall population, treatment with vutrisiran resulted in fewer patients experiencing ≥40% decreases in eGFR from baseline during the double-blind period, compared to placebo (12.7% vs 21.2%).

In patients in the overall population who progressed to CKD Stage 4 or greater during the double-blind period, treatment with vutrisiran reduced the risk of ACM and CV events (hazard ratio [HR] 0.47; 95% confidence interval [CI]: 0.26–0.85), compared to placebo.

In both analyses, results observed in patients who progressed to CKD Stage 4 or greater were consistent across the overall population, vutrisiran monotherapy, and baseline tafamidis treatment groups, and were also consistent with vutrisiran’s established efficacy profile from the primary HELIOS-B analysis.

The safety profile of vutrisiran in patients who advanced to CKD Stage 4 or greater was comparable with that established in the overall population of the HELIOS-B study.

“The new HELIOS-B analyses add depth to the growing body of evidence supporting AMVUTTRA’s first-line potential in ATTR-CM treatment,” said John Vest, M.D., Senior Vice President, TTR Global Clinical Lead, Alnylam. “From heart structure and function to renal health, the benefits observed are consistent across a wide range of measures and analyses, underscoring the potential for protection of the multiple organs impacted by this systemic disease. These findings build on the broadening dataset from HELIOS-B and continue to support the potential of AMVUTTRA to provide meaningful clinical benefit for patients living with this rapidly progressive multisystem disease.”

Data from the HELIOS-B study supported the approvals of AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary ATTR-CM in adults in the United States (US), Brazil, European Union (EU), Japan, United Arab Emirates (UAE), United Kingdom (UK), and Switzerland. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year. Collectively, AMVUTTRA has more than 8,000 patient-years of experience worldwide and is the first RNAi therapeutic approved for the treatment of both ATTR-CM and hATTR-PN in adults.

For additional information on Alnylam’s presentations in ATTR-CM at the AHA 2025 Scientific Sessions, please visit Capella.

Indications and Important Safety Information

Indications Approved by the U.S. FDA

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full U.S. Prescribing Information (revised March 2025)

About AMVUTTRA

AMVUTTRA® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. It is marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults and it is also approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults in the US, EU, UK, Brazil, Japan, Switzerland, and UAE. In a clinical study, AMVUTTRA rapidly knocked down TTR in as early as six weeks and decreased TTR levels by 87% with two and a half years of treatment. Administered quarterly via subcutaneous injection, AMVUTTRA is the first and only RNAi therapeutic approved for the treatment of both the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR).

About ATTR

Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart, and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000 – 300,000 people worldwide.1-4

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today.5 Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine.6 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made.5 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio® (inclisiran) and Qfitlia™ (fitusiran), which are being developed and commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

Alnylam Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam’s expectations regarding the safety and efficacy of vutrisiran as a treatment for ATTR-CM, including vutrisiran’s impact on measures of cardiac structure and function; the potential for treatment with AMVUTTRA to result in regression of amyloid burden in some patients; the potential of AMVUTTRA to slow disease progression and to reverse some of the structural damage caused by amyloid deposition in the heart in some patients; the potential impact of vutrisiran on key organs affected by ATTR-CM; AMVUTTRA’s potential to be a first-line treatment for ATTR-CM; AMVUTTRA’s potential to protect multiple organs impacted by ATTR-CM and to deliver meaningful clinical benefit for patients living with ATTR-CM; and Alnylam’s ability to execute on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to Alnylam’s ability to successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; the possibility of unfavorable new clinical data and further analyses of existing clinical data; interim and preliminary data; the possibility that clinical data are subject to differing interpretations and assessments by regulatory agencies; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam’s approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam’s product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation; the potential risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing Alnylam’s views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

References

1 Hawkins PN, Ando Y, Dispenzeri A, et al. Ann Med. 2015;47(8):625-638.

2 Gertz MA. Am J Manag Care. 2017;23(7):S107-S112.

3 Conceicao I, Gonzalez-Duarte A, Obici L, et al. J Peripher Nerv Syst. 2016;21:5-9.

4 Ando Y, Coelho T, Berk JL, et al. Orphanet J Rare Dis. 2013;8:31.

5 Elbashir SM, Harborth J, Lendeckel W, et al. Nature. 2001;411(6836):494-498.

6 Zamore P. Cell. 2006;127(5):1083-1086.

More News From Alnylam Pharmaceuticals, Inc.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2026.

So what: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants misrepresented and failed to disclose key facts about Inspire V, a sleep apnea device, including the actual market demand for the device and whether Inspire Medical had taken the steps necessary to launch it. Defendants issued a series of materially false and misleading statements that led investors to believe that demand for Inspire V was strong and that Inspire Medical had taken the necessary steps for a successful launch. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the on.

Short-seller James Chanos has closed his short position against Strategy after the firm's premium over its bitcoin holdings shrank, validating his bearish thesis.

The cryptocurrency market is once again under pressure, with Bitcoin (BTC) struggling to hold above critical support levels. After a brief recovery in October, BTC has slipped nearly 6% over the past week, according to CoinGecko data.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Cardano price surged by 10% amid renewed interest from retail investors, signaling a potential shift in market sentiment. ADA is currently holding strong above the crucial $0.50 support level, showing resilience despite recent market volatility. 

This price action comes as the broader crypto market rebounded slightly, gaining 0.73% after experiencing a significant weekly pullback. Buyers have begun stepping in, defending the key support zone and hinting at renewed bullish momentum. The price now consolidates within a narrowing range, pointing to an imminent breakout opportunity.

Cardano Price Eyes $1 Target as Accumulation Trend Gains Momentum
Cardano price may be preparing for a rebound after significant market movements this week. Reports indicate that large holders, known as whales, have offloaded around 4 million ADA. However, this selling pressure appears to be easing, while smaller investors are beginning to accumulate tokens again. Analysts predict Cardano price recovery, which this shift could signal the start of a bullish phase.

Market indicators also show growing confidence. Open interest and derivatives activity are trending bullish, hinting at renewed optimism among traders. With retail investors re-entering and buying pressure strengthening, some market watchers are eyeing a potential move toward the $1 mark. Whether ADA can sustain this momentum remains to be seen, but sentiment across the market is clearly improving.

$ADA Update: Whales sold 4M ADA, but retail accumulation & rising taker buy dominance hint a $1 target

Signs of a shift:

• Whale pressure easing

• Retail re-entering

• Open Interest & derivatives bullish

Could this be the start of ADA’s rebound?

Shared Via @coinexcreators pic.twitter.com/E2lONrgwn5

— Jack (@WispOfDeFi) November 8, 2025

Is ADA Price Preparing for a Major Breakout Above $0.60?
The latest ADA price surged to $0.5626, with more than 10% in the past session.  The 4-hour chart reveals that ADA is stabilizing between the $0.50 support and the $0.60 resistance range. 

If ADA sustains above $0.55, the next resistance levels are seen around $0.70, $0.80, and $1.00. As the crypto market recovers, the full Cardano forecast report is bullish.

Source: ADA/USD 4-hour chart: Tradingview
However, failure to hold this level could push prices back toward the $0.50 and $0.45 support zones.  The MACD indicator currently shows a mild bullish crossover, with the MACD line slightly above the signal line. This suggests improving momentum, though strength remains limited. A continued rise in the histogram bars could confirm an ongoing short-term uptrend. The Relative Strength Index (RSI) stands at 52, hovering near the neutral zone.

Ethereum's price rebounded to nearly $3,500 on a recent Friday, marking a 4.5% increase after initially dipping to $3,200. Despite these fluctuations and an overall decline throughout the month, analysts continue to express optimism about the cryptocurrency's potential for growth.

Trump Media and Technology Group (TMTG) now holds more than 11,500 Bitcoin worth over $1.3 billion, yet the company continues to post steep losses.Meanwhile, several Trump-linked ventures have simultaneously expanded their crypto exposure, bringing their combined holdings into the multibillion-dollar range.The trend reflects a coordinated political and commercial push to frame digital assets as both a strategic reserve and a core part of the administration’s policy agenda.Trump Media and Technology Group (TMTG), the media company associated with US President Donald Trump, now holds more than 11,500 Bitcoin, valued at over $1.3 billion.

The disclosure marks the company’s largest confirmed allocation to date and places it among the biggest public-sector corporate holders of Bitcoin.

Sponsored

Sponsored

TMTG Bitcoin Holdings Fail to Yield GainsTMTG accelerated its pivot earlier this year when it formally adopted Bitcoin as a core reserve asset.

At the time, TMTG said the company turned to BTC to protect itself from what he described as harassment and discriminatory treatment by financial institutions.

That argument tied Trump Media’s strategy to a wider corporate trend in which firms use Bitcoin to limit perceived dependence on banks that can freeze, slow, or scrutinize accounts.

Trump Media’s Bitcoin Holdings. Source: SECMeanwhile, the company’s holdings extend beyond Bitcoin. TMTG reported owning roughly 756 million Cronos (CRO) tokens, worth approximately $110 million.

The position reflects the company’s growing alignment with Crypto.com, a relationship that has already produced several crypto-focused initiatives, including exchange-traded products and promotional tie-ins.

These initiatives helped position TMTG as a more active participant in the crypto economy, even though they have not reversed the firm’s financial challenges.

Sponsored

Sponsored

TMTG posted a $54.8 million net loss in the third quarter of 2025, extending its stretch of multi-million-dollar quarterly losses.

This suggests that the company’s crypto-heavy strategy has therefore served more as a political and operational statement than a source of near-term financial relief.

Trump’s Family Crypto Holdings SurgeAs TMTG increased its exposure, other Trump-connected ventures expanded theirs as well, creating a broader cluster of politically adjacent crypto holdings.

Data from Arkham Intelligence indicates that several affiliated entities now hold substantial balances.

Other notable Trump Family entities:

Donald Trump: holds $861K in crypto
World Liberty Fi: holds $5.76B in crypto
Official Trump Meme: holds $6.30B in crypto
Official Melania Meme: holds $19.65M in crypto
Trump Cards: holds $29.72K in crypto pic.twitter.com/T12F6yP4Oh

— Arkham (@arkham) November 8, 2025
Trump personally holds about $861,000 worth of digital assets, while World Liberty Financial, one of the largest Trump-associated projects, controls more than $5.7 billion in crypto.

Additional holdings include $6.3 billion tied to Official Trump Meme, $19.65 million linked to Official Melania Meme, and nearly $30,000 associated with the Trump Cards collection.

These positions grew as the White House intensified its pro-crypto messaging, which shaped both the political environment and the commercial incentives for Trump-aligned ventures to deepen their involvement.

Taken together, the holdings show a coordinated embrace of digital assets across Trump-linked entities. They also reflect the administration’s broader effort to position crypto as both a strategic asset and a policy priority.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

The Dogecoin and Shiba Inu prices are down today after a brief rebound yesterday. Crypto pundit Nobler has suggested that these price declines are due to price manipulation rather than a wave of sell-offs among investors. 

CoinMarketCap data shows that the Dogecoin and Shiba Inu prices are on the decline today, following significant gains yesterday. In an X post, Nobler stated that Binance, Wintermute, and BlackRock were all selling Bitcoin ahead of the Federal Reserve’s announcement. This explains the DOGE and SHIB decline given the meme coins’ correlation with the flagship crypto. 

Nobler alleged that these firms have sold over $1.5 billion in Bitcoin and continue to sell more. The pundit added that there was too much market manipulation. Bitcoin is currently struggling to hold above the $100,000 level, which has sparked a bearish sentiment towards the Dogecoin and Shiba Inu prices. 

The Dogecoin price is currently trading way below the psychological $0.2 level, while the Shiba Inu price continues to underperform, down over 53% since the start of the year. The foremost meme coins are also at risk of a further decline, with speculations that the crypto market might already be in a bear market.

Market maker Wintermute recently claimed that liquidity has stopped flowing into the crypto market, which is why the bull market has halted while the Dogecoin and Shiba Inu prices decline. The market maker further noted that momentum in stablecoins, ETFs, and digital asset treasuries (DATs) has slowed, highlighting a liquidity drain in the market. 

Source: Chart from Nobler on X
Notably, companies such as CleanCore and Bit Origin had accumulated DOGE earlier in the year but have since slowed their purchase of the foremost meme coin. Meanwhile, Santiment data also showed that there has been a drop in DOGE and SHIB whale transactions, which also explained the decline in the Dogecoin and Shiba Inu prices. 

Macro Target For DOGE Still Remains $1
Despite the recent decline in the Dogecoin price, crypto analyst XForce stated that the macro target for DOGE remains between $1 and $2, which would mark new all-time highs (ATHs) for the foremost meme coin. He noted that DOGE has arguably been one of the best idealized Elliot wave 5-wave structures on the macro up to the wave 4 termination point. 

Furthermore, XForce remarked that the only bullish option left will be observed as an Expanding Ending Diagonal, as impulsive options are now off the table. Meanwhile, crypto pundit SHIB Booster stated that the Shiba Inu price could rally soon as tokens from last bull season are now recording significant gains. The pundit added that a small wave of momentum could send the SHIB price back toward the mid-range, around $0.00001603.

DOGE trading at $0.17 on the 1D chart | Source: DOGEUSDT on Tradingview.com
Featured image from Getty Images, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

Journalist

Posted: November 9, 2025

Key Takeaways
Why is Litecoin showing strength this cycle?
Litecoin is decoupling from the altcoin pack with +11.83% vs. BTC, boosted by whale accumulation and risk-off hedging.

Is the rally backed by real on-chain activity?
LTC’s DeFi TVL jumped 12%, daily on-chain volume hit $15.1 billion, and 6% more 100k+ wallets signal long-term locking.

Litecoin [LTC] is breaking away from the broader altcoin pack.

After a 4.8% rally so far in November, LTC is one of the few coins kicking off the month on a bullish note. To put that into perspective, Ethereum [ETH] is down 10%, so there hasn’t really been any alt rotation this cycle.

Against this backdrop, LTC’s relative strength stands out. In fact, it’s also showing strong momentum vs. Bitcoin [BTC], up 11.83%, which gives it an edge as traders look to hedge in a risk-off environment.

Source: TradingView (LTC/USD)

But does this resilience actually show up on-chain?

Notably, on the DeFi side, Litecoin is seeing a solid 12% jump in its Total Value Locked (TVL), hitting $2.1 million. That’s $240k flowing into LTC’s DeFi stack, boosting liquidity and showing growing on-chain activity.

Why does this matter? Rising TVL signals that more capital is being deployed into the network, creating a divergence. In other words, LTC isn’t just seeing rapid moves. Instead, there’s real long-term locking of funds.

Against this setup, LTC is carving out solid resistance at $108, which looks more like a cooldown than a full-on sell-off. So, if it breaks through (even in a risk-off market) could Litecoin be flexing as a real Q4 contender?

Litecoin tops $102 as whales and record volume drive the run
Litecoin is showing real conviction at key resistance.

On-chain metrics from Santiment highlight why the bullish momentum could continue. Over the past three months, the number of 100k+ LTC wallets has grown by 6%, signaling that big players are steadily stacking.

Meanwhile, daily on-chain volume has hit an all-time high of $15.1 billion, showing heavy network activity. Together, these signals show LTC’s gains are grounded in real network participation rather than hype-driven pumps.

Source: Santiment

The result? Litecoin has kept Q4 losses to just 7.5%.

By contrast, ETH is down 17%, highlighting how whale accumulation and network growth have fueled LTC’s relative strength in the market. If this trend sticks, breaking past the $102 resistance wall could be just the start.

From here, Litecoin has a real shot at stacking momentum. With LTC already leading the top-cap altcoins, a continued push could put it among the biggest gainers of Q4, making it a must-watch asset.

Ritika Gupta is a Financial Journalist and Geopolitical Analyst at AMBCrypto, specializing in the critical intersection of world politics, economic policy, and the cryptocurrency markets. Her analysis is informed by her distinguished background, which includes professional experience at major news network.
She holds a Bachelor's degree in Political Science and Psychology from Gargi College, University of Delhi. This academic training provides her with a sophisticated framework for dissecting complex issues such as international regulations, government fiscal policies, and the geopolitical forces that directly influence asset valuations.
At AMBCrypto, Ritika applies this expert lens to synthesize macroeconomic data and political developments, offering readers a deeper context for market movements. She excels at explaining not just what is happening in the market, but why it is happening. Her work is dedicated to providing strategic insights that empower readers to understand the complex relationship between global events and their digital assets.

“OG Bitcoin whales are dumping,” is the overarching narrative surrounding the latest Bitcoin selloff. Yet, amid nonstop chatter that Bitcoin’s earliest supporters are behind its latest price slide, on-chain analyst Willy Woo points to “nuance” in the metrics. On-chain moves don’t tell the full story; the old-guard may not be caving in just yet.

Are OG Bitcoin whales cashing out? The narrativeCharles Edwards of Capriole Investments published a chart painting 2025 as a “very colorful” year for whale activity, with a string of $100 million and $500 million Bitcoin spends traced from addresses untouched for more than seven years. He concluded:

“OG Bitcoin whales are dumping.”

OG Bitcoin whales are dumpingOver 1 million BTC have moved since June, dramatically outpacing prior cycles and handing analysts the simple conclusion that whales are cashing out. Alex Krüger highlighted how this pattern marks a break from previous market cycles. Whale selling has been steady for nearly 12 months, contributing to Bitcoin’s underperformance against other risk assets.​ He stated:

“Chart shows OG Bitcoin whales have been dumping non-stop since November 2024.”

Horizon’s Joe Consorti chimed in, posting:

“OG bitcoin whales are dumping and sentiment is horrible.”

He noted how much the market has changed as Bitcoin’s early advocates are giving way to TradFi giants like JPMorgan, and “99.5% of funds in the spot bitcoin ETFs haven’t sold in this 20% drawdown”

ETF investors: The “boomers” who didn’t flinchAnd while insiders appear to be fleeing like rats from a sinking ship, senior ETF analyst at Bloomberg, Eric Balchunas, points out that the “boomer” Bitcoin ETF buyers are holding strong. Bitcoin ETFs have seen less than $1 billion in outflows, even as spot Bitcoin fell 20%. He questioned:

“So who’s been selling? To quote that horror movie, “ma’am, the call is coming from inside the house”

The ‘nuance’ beneath OG Bitcoin whales’ movesYet amid the supposed avalanche of OG selling, Willy Woo, widely respected for on-chain analytics, cautions against reading every movement of ancient coins as dumping. His analysis points out three key things often misinterpreted as sales but which may have nothing to do with price-driven liquidation:

Address Upgrades: Many OG holders are moving coins from legacy addresses to Taproot addresses, seeking quantum security (not liquidating for cash).​Custody Rotations: Coins may be shifted to institutional custody (e.g., with Sygnum Bank) for better protection against physical theft and wrench attacks, or posted as collateral to borrow against, with no sale required.​Treasury Participation: Some “OG” coins are being moved into equity wrappers or treasury companies, allowing holders to leverage, borrow, or optimize their holdings without triggering a taxable sale.​Woo points out that on-chain data only shows coins “moving,” not the real-world intent behind the transaction. So while headline charts point to OG Bitcoin whales “dumping,” the resilience of price under this massive movement highlights market absorption and deeper reasons than just whales cashing out.​

Data from Capriole, Bloomberg, and top traders all confirm heavy OG activity, but ETF outflows remain minimal, and the price, while pressured, absorbed more than 1 million BTC in sales with far less carnage than past cycles. Not all ancient coin movement is dumping, so pay attention to on-chain nuance rather than the rumors. What you see may not be what you get.

Hyperliquid is testing a borrowing and lending module on its Hypercore testnet, hinting at a potential move toward a native money-market layer.The experiment surfaced as researchers linked the feature to broader plans for safer multi-margin trading through verifiable lending pools.At the same time, users are facing security risks after a fake Hyperliquid app appeared on Google Play, stealing more than $281,000 through phishing attacks.Hyperliquid is experimenting with a borrowing and lending module on its Hypercore testnet, signaling a potential expansion of the platform’s core offering.

The development surfaced after on-chain researcher MLM noted that the team has begun running tests for a feature labeled BLP, which he believes stands for BorrowLendingProtocol.

Sponsored

Sponsored

Is Hyperliquid Exploring a Native Lending Market?His finding suggests that Hyperliquid may be preparing to introduce a native money-market layer on Hypercore. This layer would support borrowing, supplying, and withdrawing assets.

MLM said the testnet version of BLP currently lists only USDC and PURR, but he noted that even limited asset support creates a foundation for something larger.

The Hyperliquid team is currently testing something called BLP on the Hypercore testnet – which I assume stands for BorrowLendingProtocol. It appears to be a native borrowing and lending market on Hypercore, with functions like borrowing, supplying, and withdrawing.

Currently,… https://t.co/4SR0DRTCFJ pic.twitter.com/2SzWWTIxZl

— MLM (@mlmabc) November 8, 2025
He argued that integrating a lending layer could help Hyperliquid introduce multi-margin trading more safely. In his view, margin positions would sit on top of verifiable lending pools rather than isolated balance sheets.

That architecture would mirror systems already used across established DeFi money markets and could make leverage more transparent for traders.

If rolled out, this feature would expand Hyperliquid’s footprint beyond perpetuals and provide users with access to DeFi functions currently missing from the ecosystem.

The move could also consolidate activity on a single platform, creating a more integrated trading environment for users who now rely on external lending markets.

Sponsored

Sponsored

Fake Hyperliquid App Sparks Security ConcernsWhile the team experiments with new functionality, Hyperliquid users are battling a separate threat: a fraudulent mobile application that has appeared on the Google Play Store.

The app mimics Hyperliquid’s branding despite the exchange not offering an official Android or iOS product. Its presence has raised questions about app-store screening standards, especially as users increasingly rely on mobile platforms for financial activity.

Crypto investigator ZachXBT warned that the fake app is designed to steal funds by phishing wallet credentials and private keys.

He identified an Ethereum address linked to the operation that has already collected more than $281,000 in stolen assets. His alert prompted users to check recent downloads and revoke permissions to avoid further losses.

Fake Hyperliquid App On Google Play StoreThe fake listing fits into a broader pattern. Several malicious developers have created look-alike applications for projects such as SushiSwap and PancakeSwap, exploiting the convenience of mobile access to mislead users.

Scammers often combine these apps with sponsored ads on Google, ensuring that fraudulent links appear above legitimate search results. This increases the likelihood that unsuspecting users click through.

As Hyperliquid experiments with new infrastructure and users search for easier access points, the coordinated wave of impersonation attempts highlights a persistent risk.

Attackers continue to target platforms as they grow, and users remain vulnerable when official mobile apps do not exist.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Cathie Wood, CEO of ARK Invest, remains confident in Bitcoin‘s (CRYPTO: BTC) future, even in the face of market volatility.

During a podcast, Wood reaffirmed her $1 million price target for the cryptocurrency. She attributed this confidence to the ongoing growth of stablecoins, which recently surpassed $300 billion in total market value.

This surge in stablecoins, she explained, signifies a pivotal moment for the digital asset market, despite the potential for short-term fluctuations in Bitcoin's price.

Wood emphasized that the increasing presence of stablecoins, though potentially dampening Bitcoin’s immediate market performance, reflects the strengthening credibility and maturation of the broader cryptocurrency ecosystem.

Also Read: Bitcoin’s Odds Of Dipping Below $100,000 This Month Stand At 52%, Says Polymarket

According to the podcast, she pointed out that these developments are crucial for long-term growth and solidify Bitcoin’s place as a leading digital asset.

Her $1 million prediction for Bitcoin has remained steadfast, even as the asset's price has experienced downturns, such as falling below $100,000 for the first time since June 2022.

According to Wood, the key drivers behind Bitcoin’s growth are both institutional involvement and the development of a more stable macroeconomic environment, with conditions set to improve around mid-December following Federal Reserve updates and new U.S. employment reports.

Wood compared Bitcoin's potential growth to gold's market trajectory, suggesting that Bitcoin could eventually capture a significant portion of gold's market cap. She acknowledged the current pressures in the digital asset market but remains optimistic that these will dissipate as the market stabilizes, potentially leading to a new phase of growth in 2026.

Despite recent challenges, Wood’s outlook on Bitcoin continues to be driven by its recognition as “digital gold” and its increasing institutional backing.

She also mentioned her belief that Bitcoin could reach as high as $650,000 by 2030, with the possibility of soaring to $1.5 million under favorable conditions.

Read Next

Wall Street Braces For $6.6 Trillion Fed Shift Amid Bitcoin Price Surge

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Some jurors were reportedly brought to tears and suffered sleepless nights while deliberating the case of two brothers accused of a $25 million fraud.

Key Takeaways 
What’s driving Worldcoin’s recent price surge and breakout attempt? 
Rising on-chain activity, record user growth, and aggressive accumulation in spot and futures markets are fueling the rally.

Could Worldcoin’s uptrend continue in the near term? 
Yes, if demand and user growth persist, WLD could break $1 and target resistance near $1.2.

Worldcoin [WLD] is attempting a breakout from a month-long descending channel. In fact, WLD successfully held $0.65 support and surged 16.7% to $0.87 before retracing to $0.82 at press time. 

Over the same window, the altcoin’s volume surged 136% to $338 million, reflecting growing on-chain activity and steady capital flow. 

But what’s behind these gains?

WorldCoin on-chain activity hits a historical high
Since its launch, Worldcoin has steadily expanded in terms of network usage, adoption, and on-chain activity. A major milestone was recently reached as active addresses hit an all-time high of 1 million.

According to Token Terminal, this represents a 170% increase in active addresses over the past 12 months.

Source: Token Terminal

Inasmuch, the network has made a more than 500k uptick in users between May and November, reflecting sustained network demand. 

On top of that, the network’s Daily Active Users have stabilized above 60k, ranging between 60k and 90k. At press time, Daily users were 64k, up 44.1% over the last three months, according to Artemis data. 

Source: Artemis

Typically, when Addresses and daily users rise in tandem, it reflects strengthening on-chain demand and growing actual engagement. 

Often, such a setup is perceived as bullish, as it suggests expanding network adoption, which tends to support price appreciation. 

Actual demand follows across the market
Significantly, amid growing network usage, most of these participants are overly bullish across both spot and futures markets. 

On the spot side, after the network crossed the 1 million mark, buyers returned to the market to accumulate. 

According to CoinGlass, Worldcoin’s Spot Netflow dropped into negative territory. As of this writing, the altcoin’s Netflow dropped to -$2.18 million from $6 million the previous day. 

Source: CoinGlass

Usually, a negative netflow indicates increased outflow, a clear sign of aggressive spot accumulation. 

Whales lead the Futures market
On the Futures side, whales have dominated the market sustainably throughout the past week. 

In fact, Futures Average Order Size data from CryptoQuant showed Big Whale Orders for seven consecutive days. 

Typically, when the market records large whale orders, it indicates increased whale participation on either the buy or sell side. 

Source: CryptoQuant

Interestingly, in the Perpetuals market on Hyperliquid, buyers have dominated mainly over the past week. According to Nansen data, investors on Hyperliquid have made more buy contracts than sell ones. 

Over the past 24 hours, for example, Worldcoin recorded 7.77 million in Buy Contracts compared to 6.4 million in Sell Contracts, as of writing. 

Source: Nansen

This suggests that these whales have been mostly buying WLD and taking strategic positions, awaiting the next move. 

Is this the start of a sustained uptrend?
According to AMBCrypto, Worldcoin rallied amid growing network adoption backed by actual demand in the spot and futures markets.

As a result, the altcoin’s Sequential Pattern Strength jumped into the positive zone, rising to 2.3, at press time, reflecting strengthening demand side.

Source: TradingView

The positive shift in this indicator reflects changing market dynamics, with buyers gaining control. Under these conditions, WLD is well-positioned for further gains.

If demand continues to rise alongside growing user activity, WLD could break the $1 resistance and aim for the parabolic SAR level near $1.2.

However, if demand weakens, the price may retrace to the $0.68 support zone.

An upcoming event may not result in gains for Nvidia.

Nvidia (NVDA +0.03%) has become the stock market's biggest star, delivering a 1,200% gain over the past three years, but the company's fame isn't due to this performance alone. It's also linked to this player's key position in one of today's biggest growth markets -- the artificial intelligence (AI) market -- and the promise of what Nvidia may achieve as this AI boom roars on.

But this doesn't mean Nvidia stock will offer investors a smooth and steady ride into the stratosphere. This stock, which continues its ascent, rising 45% so far this year, at certain points may lose momentum. This already happened earlier in the year amid concerns about AI spending and the impact of President Donald Trump's tariffs on semiconductor imports.

Those worries have since disappeared, but in the coming weeks, Nvidia may be heading for another rough patch. In fact, my prediction is Nvidia stock is going to stall out on Nov. 20, following a key moment for the company. Let's take a closer look.

Image source: Getty Images.

Nvidia's big bet
Before jumping in, we'll start by considering the Nvidia story so far. The company is a designer of graphics processing units (GPUs), chips that power the most essential of AI tasks like the training and inferencing of models. Nvidia went all in on AI before the real boom even began, tailoring its GPUs for this purpose. It was a major bet, and it turned out to be the perfect one. Thanks to this move, Nvidia established its leadership early, and thanks to its ongoing innovation, it's maintaining this position.

All of this has resulted in massive revenue growth for the company -- for example, in the latest fiscal year, Nvidia's revenue soared in the triple-digits to a record of more than $130 billion. Nvidia also has wowed investors with its profitability on sales, as seen through gross margins of more than 70%.

Today's Change

(

0.03

%) $

0.05

Current Price

$

188.13

Now, let's consider the event that's coming up after the closing bell on Nov. 19, and this is Nvidia's fiscal 2026 third-quarter earnings report. I'm optimistic that this will be another great moment for Nvidia -- after all, chief Jensen Huang recently said total cumulative shipments of its current Blackwell and the upcoming Rubin platform as well as networking products so far total half a trillion dollars over 2025 and 2026. And the manufacturer of Nvidia chips -- Taiwan Semiconductor Manufacturing -- as well as Nvidia customers such as Oracle recently have spoken of strong AI demand.

Why Nvidia stock may fall
So, clues suggest Nvidia, too, will speak of a successful third quarter. Considering all of this, why do I expect Nvidia stock to stall out following the news? In recent days, some investors and analysts have expressed concern about a potential bubble in the AI market -- even if a bubble isn't forming, the presence of these worries has been weighing on technology stocks, and this may continue. For example, Palantir Technologies hit it out of the park, announcing explosive quarterly earnings growth, and the stock fell in the trading session following the report.

It's also true that valuations have climbed, and though Nvidia remains reasonably priced considering its long-term potential, at 43x forward earnings estimates the stock still is much pricier than it was earlier this year.

NVDA PE Ratio (Forward) data by YCharts

Finally, after Nvidia's most recent report -- which was extremely positive -- the stock slipped about 4% in the days that followed. So, a solid earnings report from Nvidia doesn't always result in fantastic stock performance.

All of this prompts me to predict that Nvidia stock will stall out following its Nov. 19 earnings report. But this doesn't mean I'm bearish on the stock, as I think any loss of momentum would be short term. In fact, I would use a dip in the shares to add to positions as I'm optimistic about Nvidia over the long haul. So, if I'm right and Nvidia stock loses momentum following its earnings report, growth investors seeking an AI winner may see this as a valuable buying opportunity.

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sotagliflozin treatment in heart failure patients with preserved ejection fraction (HFpEF), and without diabetes, across a range of measures, including cardiac structure and function, quality of life and functional capacity.

Conducted under the direction of Dr. Juan J Badimon, PhD, FACC, FAHA, director, Atherothrombosis Research Unit, professor of Medicine/Cardiology at Mount Sinai Medical Center in New York City, “SOTA P CARDIA: A Randomized Trial of Sotagliflozin in HFpEF Patients without Diabetes” was a prospective, randomized, double-blind, placebo-controlled trial that exclusively enrolled patients with HFpEF, the most rapidly increasing form of heart failure.

The objective of the study was to compare treatment with sotagliflozin to placebo on a number of cardiac functional and structural measures, such as left ventricular mass, diastolic function, standard six-minute walk test, and KCCQ. The study enrolled 88 participants who were racially diverse and 70 percent female. Patients were treated with sotagliflozin or placebo for six months, and comparisons were made between groups during and after completion of treatment.

Treatment with sotagliflozin resulted in statistically significant improvements in left ventricular mass, diastolic function, capacity for a six-minute walk test, and KCCQ measurements. In addition, though peak VO2 improvement did not achieve statistical significance, there was a notable improvement after treatment with sotagliflozin.

“The benefits observed with sotagliflozin treatment in the study include significant improvements in cardiac structure and function, symptom relief and, most importantly, quality of life and functional capacity,” said Dr. Badimon. “Although sotagliflozin was approved more than two years ago for heart failure patients with or without diabetes, our study is the first to demonstrate important clinical benefits for patients with preserved ejection fraction without diabetes.”

According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent hospitalizations and has a one-year risk of death of roughly 25 percent.

“When you combine these study results with previously reported data on reductions among patients treated with sotagliflozin in the risks for MACE and rehospitalization following previous hospitalization for acute heart failure events, the potential for sotagliflozin to be considered a different class of medication starts to come into focus,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.

Click here and search for “SOTA P CARDIA” to access the study abstract.

About Sotagliflozin 
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also currently under investigation for another cardiac condition, hypertrophic cardiomyopathy (HCM). 

About Lexicon Pharmaceuticals    
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, HCM, obesity, metabolism and other indications.  For additional information, please visit www.lexpharma.com.

Safe Harbor Statement    
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin and its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.    

For Investor and Media Inquiries:   

Lisa DeFrancesco    
Lexicon Pharmaceuticals, Inc.   
[email protected]  

November 08, 2025 2:31 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Zions Bancorporation, N.A. (NASDAQ: ZION) (NASDAQ: ZIONP) resulting from allegations that Zions Bancorporation may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Zions Bancorporation securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46354 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On October 15, 2025, Zions Bancorporation announced that it would be taking a $50 million charge-off for a loan underwritten by its wholly-owned subsidiary, California Bank & Trust, in light of "apparent misrepresentations and contractual defaults by the Borrowers and Obligors and other irregularities with respect to the Loans and collateral." Zions Bancorporation further disclosed that it would be engaging counsel to coordinate an independent review of the matter.

On this news, Zions Bancorporation's common stock fell 13.14% on October 16, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273696